Literature DB >> 34301761

Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of In Vivo Fallopian Tube Electroporation and CRISPR-Cas9-Mediated Genome Editing.

Katie Teng1,2, Matthew J Ford1,2, Keerthana Harwalkar1,2, YuQi Li1,2, Alain S Pacis3, David Farnell4,5, Nobuko Yamanaka1, Yu-Chang Wang2,6, Dunarel Badescu2,6, Tuyet Nhung Ton Nu7, Jiannis Ragoussis2,6,8, David G Huntsman4,5, Jocelyne Arseneau7, Yojiro Yamanaka9,2.   

Abstract

Ovarian cancer is the most lethal gynecologic cancer to date. High-grade serous ovarian carcinoma (HGSOC) accounts for most ovarian cancer cases, and it is most frequently diagnosed at advanced stages. Here, we developed a novel strategy to generate somatic ovarian cancer mouse models using a combination of in vivo electroporation and CRISPR-Cas9-mediated genome editing. Mutation of tumor suppressor genes associated with HGSOC in two different combinations (Brca1, Tp53, Pten with and without Lkb1) resulted in successfully generation of HGSOC, albeit with different latencies and pathophysiology. Implementing Cre lineage tracing in this system enabled visualization of peritoneal micrometastases in an immune-competent environment. In addition, these models displayed copy number alterations and phenotypes similar to human HGSOC. Because this strategy is flexible in selecting mutation combinations and targeting areas, it could prove highly useful for generating mouse models to advance the understanding and treatment of ovarian cancer. SIGNIFICANCE: This study unveils a new strategy to generate genetic mouse models of ovarian cancer with high flexibility in selecting mutation combinations and targeting areas. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34301761     DOI: 10.1158/0008-5472.CAN-20-1518

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.

Authors:  Beatriz Álvarez-Abril; Elena García-Martínez; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2022-03-17       Impact factor: 8.110

2.  Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.

Authors:  Stella V Paffenholz; Camilla Salvagno; Yu-Jui Ho; Matthew Limjoco; Timour Baslan; Sha Tian; Amanda Kulick; Elisa de Stanchina; John E Wilkinson; Francisco M Barriga; Dmitriy Zamarin; Juan R Cubillos-Ruiz; Josef Leibold; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-01       Impact factor: 11.205

Review 3.  Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.

Authors:  Alessandra Ciucci; Marianna Buttarelli; Anna Fagotti; Giovanni Scambia; Daniela Gallo
Journal:  Cell Mol Life Sci       Date:  2022-06-16       Impact factor: 9.207

Review 4.  Harnessing preclinical models for the interrogation of ovarian cancer.

Authors:  Tianyu Qin; Junpeng Fan; Funian Lu; Li Zhang; Chen Liu; Qiyue Xiong; Yang Zhao; Gang Chen; Chaoyang Sun
Journal:  J Exp Clin Cancer Res       Date:  2022-09-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.